Table 2 Estimates of efficacy endpoints by subtype (N = 77).
From: Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
LMS | UPS, MFS | Chondrosarcoma | DDLPS | Osteo-sarcoma | Angio- sarcoma | ASPS | SBRCT or synovial sarcoma | Other | |
|---|---|---|---|---|---|---|---|---|---|
PR | 1/10 | 2/10 | 1/10 | 0/10 | 0/10 | 3/8 | 1/4 | 0/5 | 1/10 |
Median DoR* (months) | 3.8 | 14.8 | 12.9 | NR | NR | 5.9 | 11.8 | NR | 16.3 |
CBR at 6 months | 20% | 20% | 20% | 37.5% | 0 | 62.5% | 50% | 0 | 10% |
Median PFS (months) | 1.8 | 2.4 | 1.8 | 3.9 | 2.0 | 7.3 | 2.6 | 2.0 | 2.1 |
Median OS (months) | 6.9 | 9.2 | 5.1 | 21.7 | 6.3 | NE | NE | 5.9 | 12.0 |
